Malaysian Genomics Explores R&D Collaboration with SIRIM ACN Newswire

Malaysian Genomics Explores R&D Collaboration with SIRIM

January 9, 2023
PETALING JAYA, Malaysia, Jan 9, 2023 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce a strategic cooperation with SIRIM Berhad, to explore the commercialisation of joint research and development (R&D) projects in the medical and biotechnology fields.Encik Sasha Nordin, Chief Executive Officer of Malaysian GenomicsSIRIM Berhad is wholly owned by the Malaysian Government, and is focused on R&D, standardisation and quality. The organisation acts as a catalyst for industrial development through programmes involving technology and standardisation.Under the strategic cooperation, both parties will evaluate the potential commercial value of a range of genomics-driven biotechnology R&D projects. These include developing biofuels and biopharmaceuticals, companion diagnostic tests for cancer treatment, and bioactive cosmeceuticals.Encik Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, "SIRIM and Malaysian Genomics have complementary experiences, resources, and technology assets. Teams from both organisations have met to explore their research and develop interests in precision medicine, food security, and products for the consumer market. This strategic collaboration will pave the way for individual agreements specific to projects for which commercial opportunities have been identified."President and Group Chief Executive Officer of SIRIM Berhad, Dato' Indera Dr Ahmad Sabirin Arshad said, "We look forward to working closely with Malaysian Genomics on R&D projects that can benefit the country and domestic industries. This strategic collaboration will expedite the relevant processes to ensure that both parties can explore the commercial viability of projects, before commencing research, development and commercialisation."The parties of this two-year strategic collaboration will also jointly source for suitable private and public institutional partners for the funding and commercialisation of these projects.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Sees Rise in Profit Margins for 1Q ACN Newswire

Malaysian Genomics Sees Rise in Profit Margins for 1Q

November 23, 2022
PETALING JAYA, Malaysia, Nov 23, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today reported a revenue of RM3.81 million for the first quarter ended 30 September 2022 (1Q 2023) versus a revenue of RM9.32 million in 1Q 2022, as the Group refocuses on immunotherapy and cell therapies under the biopharmaceutical business and pushes for organic growth of its genetic screening business.Independent Non-Executive Chairman, Dato' Seri Dr Chen Chaw MinThe Group recorded a 254.16% increase in profit before tax (PBT) to RM0.85 million for 1Q 2023, compared with RM0.24 million in the corresponding quarter of the previous financial year, on higher profit margins and revenue contributions from the new biopharmaceutical business.Earnings per share for 1Q 2023 stood at 0.68 sen compared with 0.20 sen in 1Q 2022.Dato' Seri Dr Chen Chaw Min, Independent Non-Executive Chairman of Malaysian Genomics said, "The Group's pivot to immunotherapy and cell therapies from vaccine distribution continues to pay off as PBT improves on higher profit margins. We expect more improvements to the biopharmaceutical business as the Group's expansion of its distribution network and footprint overseas in the Middle East and Southeast Asia takes shape.""We are pushing the genetic screening business as the Group continues to reach out through business-to-consumer channels for a wider market reach. We believe better awareness and education is prompting more people to take action on how they can enhance their health, and the Group will leverage on this through catering to the different needs and groups from our suite of healthcare-related solutions. We are also seeking to acquire assets or invest in businesses that will support the expanded market reach of our products and services.""The Group is well positioned to be a leading provider of genetic screening, genome analysis, and biopharmaceutical products in Southeast Asia, as we are equipped with a high-throughput sequencing lab, an advanced microarray facility, and a new state-of-the-art cGMP cell processing lab for cell therapies, including immunotherapy for various types of cancers. We are confident that we are in a position to provide patients with better access to the latest precision and personalised healthcare solutions."Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Signs Strategic Collaboration Agreement for Expansion in the UAE ACN Newswire

Malaysian Genomics Signs Strategic Collaboration Agreement for Expansion in the UAE

October 26, 2022
United Arab Emirates (UAE), Oct 26, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced the signing of a Strategic Collaboration Agreement (SCA) outlining partnerships to market and distribute the Group's Dtect(R) range of genetic screening services in the United Arab Emirates (UAE).Consul General of Malaysian Consulate in Dubai Mohd Fadly Amri Aliaman; ED of Malaysian Genomics Azri Azerai; Co-Founder/Director of Wellness by Design Dr. Lama Al Naeli; Chairman of ASC, BALSAM and Wellness by Design Dr Hisham Hakim; CEO of Balsam Health Services Abdulkader Awad; CEO of IAC Nurul Faten Jasmee; Director of ASC Kair Hakim and Secretary General of Malaysian Business Council Izwan Adnan [L-R]Director of ASC Kair Hakim; ED of Malaysian Genomics Azri Azerai; Consul General of Malaysian Consulate in Dubai Mohd Fadly Amri Aliaman; Chairman of ASC, BALSAM and Wellness by Design Dr Hisham Hakim; CEO of Balsam Health Services Abdulkader Awad, and CEO of IAC Nurul Faten Jasmee [L-R]Other than Malaysian Genomics, the SCA involves American Spine Center (ASC), a Dubai, UAE-based specialist in spinal injury and spine pathology; BALSAM Health Services, a Dubai, UAE-based healthcare service provider; Wellness by Design FZ LLC, a Dubai, UAE-based nutrition, obesity and weight loss specialist, and Sharjah, UAE-based IAC International LLC.Under the SCA, Malaysian Genomics, ASC, Balsam and Wellness by Design will explore common strategies for joint or allied projects that translate to innovative healthcare tools or solutions, while the role of IAC is to support activities in priority areas, aligning the parties and work with other organisations, where appropriate. IAC will also be the point of contact between Malaysian Genomics and ASC, Balsam and Wellness by Design.Noor Azri bin Dato' Sri Noor Azerai, Executive Director of Malaysian Genomics, said, "The SCA will allow us to formally explore how the parties can work together, including technical trials and evaluation of our Dtect screening tests for commercialisation in the UAE. Malaysian Genomics' role will be to provide technical and scientific support under the SCA. In addition, we constantly look for opportunities to partner with like-minded businesses and organisations in expanding our market reach for Dtect and our other services."Dr. Hisham Hakim, Chairman of ASC, BALSAM and Wellness by Design, said, "We welcome this first step in a working relationship with Malaysian Genomics and IAC, and look forward to the inclusion of Dtect to offer more choices to our patients. We are committed to clinical and technological excellence as we bring coordinated patient care with compassion and commitment while ensuring cost efficiency."Ms. Nurul Faten Jasmee, CEO of IAC, said, "There are lots of opportunities for the expansion of genetic screening services in the UAE and the wider Middle East and North Africa (MENA) region. We will provide the coordination, business delivery and project management between the parties during the technical trials for Dtect in the UAE, followed by the commercial rollout and expansion throughout the MENA region."Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Grows Presence in Thailand ACN Newswire

Malaysian Genomics Grows Presence in Thailand

September 23, 2022
PETALING JAYA, Malaysia, Sep 23, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce today a series of collaborations to grow its customer base in Thailand as well as exploring opportunities for research and development (R&D) of new products and services.Ms. Songsuda Panich, Founder of Marine Group; Encik Sasha Nordin, Chief Executive Officer of Malaysian Genomics; Mr. Choy Hong Yang, Director of Salus Holdings [L-R]Chief Executive Officer of Malaysian Genomics, Encik Sasha NordinThe Group signed a supply and collaboration agreement with Acquest Healthcare Stem Cell Research and Development Co. Ltd. to produce CAR T-cells for supply to Acquest's customers. Acquest is a well-established provider of various cell therapies to hospitals, specialist doctors, and patients in Thailand. It operates a state-of-the-art clinical laboratory and also the largest privately-owned specialty human cell culturing facility in the country.The Group also signed a supply and collaboration agreement with Salus Holdings Co. Ltd. ("Salus") to supply biopharmaceutical and genomics products and services to Salus' customers. Salus is a specialist in wellness and health screening using science and technology for early disease detection and managing programmes for lifestyle intervention based in Bangkok, Thailand. Finally, the Group signed a Letter of Intent with Marine Group Co. Ltd. and Salus on collaborative research in the use of genetic screening tests and formulated cosmetic products containing certain cell therapy ingredients on the regeneration of skin and hair of patients. Marine Group is an aesthetic and wellness specialist with a network of over 42 centres under the brands Slim Up(TM), Skin Doctors(TM), and Biocell(TM).The signing ceremony was attended by His Excellency Dato' Jojie Samuel, Ambassador of Malaysia to Thailand and Encik Mohamed Hafiz Md Shariff, Trade Commissioner of MATRADE Bangkok.Chief Executive Officer of Malaysian Genomics, Encik Sasha Nordin, said, "We are looking forward to a fruitful relationship with our Thai partners, Salus and Acquest. These collaborations are part of our strategy of growing our customer base and increasing our presence overseas through working with business partners who have an established presence in their respective market segments."Dr. Roland Neff, CEO of Acquest, said, "This collaboration is the first step as both parties explore the possibilities of conducting joint R&D that can result in new products and services that can be commercialised. We have a state-of-the-art clinical laboratory in Bangkok and also the largest privately-owned specialty human cell culturing facility in the country."Mr. Choy Hong Yang, Director of Salus, said, "At Salus, we use science and technology to provide services on disease detection, prevention and life-span improvement. This collaboration with Malaysian Genomics will enable us to leverage on their genetics knowledge and expertise to offer more products and services while the strategic cooperation is in keeping with our core value of joint innovation to offer new technologies to our customers."Ms. Songsuda Panich, Founder of Marine Group, said, "Skin Doctor, Slim Up and BioCell centres are always striving to provide the latest in skin and aesthetic science and technology for our customers. We look forward to collaborating with Malaysian Genomics and with Salus Healthcare on research and development involving cell regeneration products."Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah ACN Newswire

Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah

September 21, 2022
PETALING JAYA, Malaysia, Sep 21, 2022 - (ACN Newswire via SEAPRWire.com) - Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw MinUnder the LOI, MGRC, which owns a high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, as well as Genotec, which specializes in biomedical treatments using stem cells, will assist in strengthening the teaching and research activities of the undergraduate programme at UMS' Faculty of Science and Natural Resources.This cooperation will enable the exchange of research resources and ideas to enhance the quality of research at UMS, as well as create opportunities for students from the Faculty of Science and Natural Resources to serve their internship period at MGRC or Genotec.Chairman of Malaysian Genomics, Datuk Seri Dr. Chen Chaw Min, said, "We are happy to assist UMS undergraduates in pursuing their R&D goals so that they have a better understanding of their field of study. This is also in support of the National Biotechnology Policy 2.0 launched recently focusing on agriculture and food security, healthcare and wellbeing, as well as industrial and the circular economy."The Dean of the Faculty of Science and Natural Resources, UMS, Professor Dr. Jualang Azlan Gansau said, "UMS is actively engaging in research as well as teaching activities and the involvement of industry is crucial in ensuring the relevance of such activities conducted at the University."The signing of the LOI followed UMS' visit to MGRC's Biosafety Level 2 cGMP (Current Good Manufacturing Practice)-certified laboratory, which is used for the production of cell therapies, including CAR T-cell therapies for various cancers.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Reports RM28.36 Million Full-Year Revenue ACN Newswire

Malaysian Genomics Reports RM28.36 Million Full-Year Revenue

August 30, 2022
PETALING JAYA, Malaysia, Aug 30, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, reported revenue of RM6.33 million for the fourth quarter ended 30 June 2022 (4Q 2022) compared with the loss of RM0.07 million in the corresponding quarter of the previous financial year (4Q 2021) on higher contribution from the biopharmaceutical business and continued organic growth of the genetic testing business.Sasha Nordin, Chief Executive Officer of Malaysian GenomicsThe Group recorded a profit before tax (PBT) of RM2.97 million for the quarter under review compared with a loss before tax (LBT) of RM2.11 million in 4Q 2021 due to higher profit margin from the biopharmaceutical business as well as efficient cost monitoring.For the financial year ended 30 June 2022 (FY2022), Malaysian Genomics registered revenue of RM28.36 million, which is an increase of RM26.58 million compared with RM1.78 million reported in the corresponding period of the previous financial year (FY2021) from growth of the biopharmaceutical business comprising of immunotherapy and cell therapies as well as COVID-19-related products and services.The Group recorded PBT of RM6.18 million for FY2022 compared with LBT of RM4.29 million in FY2021 mainly due to higher revenue as a result of higher margin as well as cost efficiencies.Earnings per share for 4Q 2022 stood at 3.25 sen compared with the loss per share of 1.94 sen in the corresponding quarter of the previous financial year.En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics said, "We continue to see improvement in the Group's financial performance, and this is attributable to the introduction of biopharmaceutical services as well as our aggressive push to market genetic testing services. Towards the tail-end of the quarter under review, we acquired a 51% stake in kidney dialysis operator Aquahealth Sdn Bhd in which we intend to introduce a holistic approach to kidney healthcare through our suite of products and services. We also have plans to open more such centres across Malaysia given the projected increase in the number of kidney patients.""We are also expanding in Southeast Asia and the Middle East with a series of agreements that we recently inked in which we collaborate with local partners to promote, market and distribute our biopharmaceutical and genetic testing services."About Malaysian Genomics Resource Centre BerhadMalaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group") is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients. For more information, visit www.mgrc.com.my. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region ACN Newswire

Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region

August 29, 2022
PETALING JAYA, Malaysia, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a Memorandum of Understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company.Noor Azri Bin Dato' Sri Noor Azerai, Executive Director of Malaysian Genomics, and H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group [L-R]Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private equity, real estate and industrial investments.As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell and exosome products. Ajlan will also identify commercial research and development (R&D) opportunities for genome sequencing and analysis in the Middle East and North Africa (MENA) region for areas such as agriculture, aquaculture, plantations, healthcare and industrial biotechnology.Malaysian Genomics on its part will analyse samples for genetic screening tests as well as provide Ajlan with genomic and bioinformatics expertise to bid for projects through Ajlan.Noor Azri Bin Dato' Sri Noor Azerai, Executive Director of Malaysian Genomics, said, "This is a really good opportunity for us to explore the MENA market for our products and services, especially in the area of R&D where we see a lot of growth especially in agriculture and aquaculture due to climate change impact and the health diagnosis for distinct population groups."H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group, said, "We look forward to working with Malaysian Genomics to bring its biopharmaceutical and genetic services and products to Saudi Arabia, which is a good launchpad to the MENA region. This MoU is just the beginning as we explore how we can work closely together in the coming months."About Malaysian Genomics Resource Centre BerhadMalaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group") is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients. For more information, visit www.mgrc.com.my. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU ACN Newswire

Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU

August 18, 2022
PETALING JAYA, Malaysia, Aug 18, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad's (Bursa: MGRC, 0155) wholly-owned subsidiary, MGRC Therapeutics Sdn. Bhd. signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange.En. Azri Azerai, Executive Director of Malaysian GenomicsDatin Dr Maya, Chief Executive Officer of MAHSA HealthMalaysian Genomics is the first company in Malaysia to pioneer genomics and genetic screening in Malaysia for over 17 years. Since then, Malaysian Genomics has expanded its offerings in other important areas in the healthcare and wellness that include cancer immunotherapy, cell manufacturing services and kidney dialysis. Malaysian Genomics continues to strive to provide the latest in precautionary, preventive and curative healthcare services for its local and worldwide customers.MAHSA Health Sdn Bhd is a Malaysia-grown company, part of MAHSA Group of Companies, which is determined to be a revolutionary leader in healthcare. Since its inception in 2017, MAHSA Health has been striving to be in the forefront of primary healthcare, focusing on family health and wellness.Encik Azri Azerai, Executive Directorof Malaysian Genomics said, "We look forward to sharing our experience in genomics, bioinformatics, and biopharmaceuticals with MAHSA Health via this collaboration. By providing industry inputs and insights to MAHSA, we hope to benefit students at MAHSA with the tremendous promise that various healthcare sciences have to offer for all.""Through this collaboration we also hope to identify opportunities to improve the delivery of integrated, holistic primary healthcare services, including genetic screening services to improve the lives of individuals in the long run."Datin Dr Maya, CEO of MAHSA Health, with her double expertise in health and wellness services, and education industry, said, "Passion is the greatest asset we each have. The main idea of MAHSA Health is to improve the quality of life in providing health care and wellness services to our community. We are a team-based healthcare that provides comprehensive medical care to patients with the goal of obtaining maximized health outcomes.""Through this collaboration, we foresee opportunities and collaborative efforts in many areas, both in health care and education industry in providing an ecosystem of teaching, training, and producing services to the country nationwide."The MoU is a framework through which MGRC Therapeutics and MAHSA Health can explore opportunities for health and wellness-related services; create opportunities for students' clinical placement, internship and employment; identify opportunities for conducting collaborative research and development (R&D); and create opportunities in training, seminars and conferences.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide ACN Newswire

UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide

July 20, 2022
PETALING JAYA, Malaysia, Jul 20, 2022 - (ACN Newswire via SEAPRWire.com) - UCrest Berhad (ACE Market: 0005) and Malaysian Genomics Resources Centre Berhad, (ACE Market: 0155) announced today that they have signed a collaborative agreement to integrate genomic testing services into digital health platform, iMedic(TM), elevating healthcare services to the next level.Dato' Dr. Mohd Fikri bin Abdullah, Independent Director of UCrest Berhad; Mr. Eg Kah Yee, Chairman and Managing Director of UCrest Berhad; En. Sasha Nordin, Chief Executive Director, Malaysian Genomics Resource Centre Berhad; Dr. Eunice Pui Wan Wen, Head of Medical Affairs, Malaysian Genomics Resource Centre Berhad[L-R]Dato' Dr. Mohd Fikri bin Abdullah, Independent Director of UCrest Berhad; Mr. Eg Kah Yee, Chairman and Managing Director of UCrest Berhad; En. Sasha Nordin, Chief Executive Director, Malaysian Genomics Resource Centre Berhad; Dr. Eunice Pui Wan Wen, Head of Medical Affairs, Malaysian Genomics Resource Centre Berhad[L-R]Under this agreement, a virtual genome service centre will be developed on iMedic platform enabling the genomic testing services of MGRC to be made available to the hospitals and clinics (B2B), widening its market access not just in Malaysia, but globally. Additionally, the genomic testing services will also be made available to patients directly (B2C). Patients' genomic data from their test results will be integrated into Electronic Medical Records (EMR) making it accessible by doctors and patients in the process of consultation and management, resulting in improved accuracy in diagnosis and treatment.UCrest is the leading technology provider of digital health platform with offices in Malaysia, Singapore, China and Taiwan providing access to thousands of doctors, including many from the leading hospitals in the United States and China, to provide online consultation and management of patients anywhere in the globe.Malaysian Genomics is a leading genomics and biopharmaceutical company in ASEAN for genome sequencing, bioinformatics analysis, and genetic screening, and various types of immunotherapy including CAR T-Cell therapy for the treatment of certain cancers.The global genomics market size was valued at US$20.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.35% from 2021 to 2028. The Asia Pacific genome sequencing market will grow by 15.6% annually over 2022-2030 due to growing government funding initiatives in genomics projects related to cancer treatment and the utilization of genomics in personalized medicine targeting chronic disease prevention and management.Mr. Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, "We are looking forward to working with UCrest as its iMedic platform will provide us an opportunity to reach out to markets beyond Malaysia. The platform will also enable us to strengthen our B2B and B2C channels. This collaboration can play an important role in providing physicians with easy access to the latest in genetic screening, in support of enhancing their medical practice and improving patient outcomes.""This partnership with Malaysian Genomics allows us to enhance our vision of integrating preventive and precision medicine into iMedic where genome data will empower the patients to better prevent and manage the chronic diseases with the online consultation of doctors," said Mr. Eg Kah Yee, Chief Executive Officer of UCrest. "Cancer, Cardiovascular Diseases (CVD), diabetic, asthma, sleep apnea and many other chronic diseases can be prevented, managed or treated more effectively with the addition of the genome services," he added.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/UCrest Berhad: 0005 [BURSA: UC] https://www.ucrest.net/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia ACN Newswire

Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia

July 13, 2022
PETALING JAYA, Malaysia, Jul 13, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that it has entered into a strategic partnership with United Doctors Hospital (UDH) for collaboration in genomics and cell therapies.Azri Azerai, Executive Director of Malaysian GenomicsUDH, located in Jeddah, Saudi Arabia, is accredited by the Saudi Central Board for Accreditation of Healthcare Institutions. UDH has also won numerous awards for social responsibility, including the King Khalid Award for Social Responsibility in 2018, and is certified with the SA8000, the world's leading social certification programme, by Social Accountability International (formerly known as Social Accountability Accreditation Services), a United States-based charitable organisation, in 2016.Under the partnership, which is valid for three years, Malaysian Genomics and UDH will take the necessary steps to encourage and promote cooperation in the sales and marketing of genetic screening tests and cell therapy products; collaboration in research and development (R&D), and other areas of cooperation in the genomics and cell therapies to be mutually decided by both parties. Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "This strategic partnership with UDH enables us to expand the geographical reach of our products and services beyond Malaysia to the Middle East and North Africa region. It will also enable us to collaborate on R&D with various domain specialists to enhance our suite of genetic screening tests and cell therapies."Dr. Hefny Moustafa Hefny, Medical Doctor at UDH, said, "Among the areas being explored by Malaysian Genomics and UDH are opportunities to develop genetic screening tests for hereditary conditions and diseases that are prevalent in the Middle East or Northern Africa, which may be different from other parts of the world."Malaysian Genomics is actively expanding its business-to-consumer channels as part of the Group's growth strategy. The Group recently acquired a 51% stake in kidney dialysis operator Aquahealth Sdn Bhd to offer personalised kidney care that also involves nutrition management, lifestyle changes, and genetic testing. It is also collaborating with AirAsia's Asean Super App online shopping platform and Speedoc to provide genetic screening services.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Proposes Private Placement ACN Newswire

Malaysian Genomics Proposes Private Placement

July 8, 2022
PETALING JAYA, Malaysia, Jul 8, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is proposing to undertake a private placement of up to 10% of its total number of issued shares or up to 12.42 million new placement shares at an issue price to be determined for third-party investors that will be identified later.Azri Azerai, Executive Director of Malaysian Genomics Resource Centre BerhadShareholders had approved in the AGM convened on 30 November 2021 for the Group to issue and allot new shares at any time and at such price as the Board of Directors deemed fit provided the number of new shares does not exceed 10% of the total number of issued shares. The new placement shares will rank equally in all respects with existing Malaysian Genomics shares except they will not be entitled to any dividends, rights, allotments and any other forms of distribution should the entitlement date precede the relevant date of allotment and issuance of the new placement shares.Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "We are proposing the private placement to raise funds mainly for the Group's future investments of which we are still exploring options and a part of the proceeds will be allocated for the purchase of equipment including IT hardware, biological safety cabinet and extraction automation for our existing and future businesses.""The reopening of the economy presents opportunities in the private healthcare segment and the fresh funds raised will enable us to be able to take advantage of the possibilities. We diversified into the biopharmaceutical business in 2020 and have since been pushing to open channels for our cell therapies and genetic tests through a series of agreements that gives us a wider market reach. We also bought a 51% stake in a kidney dialysis operator, Aquahealth Sdn Bhd, to offer holistic kidney care."UOB Kay Hian Securities (M) Sdn Bhd is the adviser and placement agent for the proposed private placement.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics to Offer First-Ever Sports-Based Tests Specific to Southeast Asian Genetic Profiles ACN Newswire

Malaysian Genomics to Offer First-Ever Sports-Based Tests Specific to Southeast Asian Genetic Profiles

July 6, 2022
PETALING JAYA, Malaysia, Jul 6, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that the Group's wholly-owned subsidiary, MGRC Therapeutics Sdn Bhd (MGRCT), is collaborating with Rinani Genotec Sdn Bhd (Genotec) to offer sports-based genetic tests.Genotec, a biomedical technology firm focusing on stem cell treatment and genetic testing, now offers a direct-to-consumer sports and fitness DNA test which enables individuals to better understand their genetic profile in sports and fitness-related areas. The test result includes categories such as energy metabolism and utilisation, muscle performance, response to cardiovascular training, weight management, nutrient metabolism, bone and joint health, and mental ability and performance. The information can then be integrated by individuals into their lifestyle in order to improve their daily sport and fitness performance.The collaboration will see both parties consult and collaborate on sports-based genetic profile testing and the marketing of these services. In addition, Genotec will also work closely with MGRCT on the marketing of Malaysian Genomics' full range of Dtect genetic screening tests.Dato' Alvin Joseph, Executive Director of MGRC, said, "This collaboration is another important step towards realising our vision of becoming a premier integrated life sciences company. By partnering with experts in sports science, we have now pioneered a genetic screening profile specifically designed for professional and amateur athletes, and everyday fitness enthusiasts. The science of genetics has a long history in professional sports and through this new profile we can support sportspeople in their pursuit of peak performance."Mr. Julian Koay, Genotec's Director of Business Development, said, "With Malaysian Genomics' experience in genetics, what we have developed can be a game-changer for athletes and sports talents. We will use this new sports genetic profile to personalise fitness, sports and recovery regimes of sportspeople, to improve their performance."Founders of Genotec, Julian Koay and Watson Chung, are the first certified DNA-based trainers in Malaysia, offering a unique programme combining knowledge of individuals' genetic profiles with a fitness or training regime that enhances the effectiveness of the fitness or training programmes.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Main Market-Bound Seng Fong Holdings Berhad IPO Shares Oversubscribed by 3.09 Times ACN Newswire

Main Market-Bound Seng Fong Holdings Berhad IPO Shares Oversubscribed by 3.09 Times

June 29, 2022
KUALA LUMPUR, Jun 29, 2022 - (ACN Newswire via SEAPRWire.com) - Tricor Investor & Issuing House Services Sdn Bhd (TIIH) is pleased to announce that the Initial Public Offering (IPO) of Seng Fong Holdings Berhad is oversubscribed by 3.09 times.Managing Director of Seng Fong, Mr. Er Hock LaiGroup Managing Director/ Chief Executive Officer of Hong Leong Investment Bank, Ms. Lee Jim LengSeng Fong's IPO involves the issuance of 160,874,300 IPO Shares in the following manner:(A) Retail offering of 42,198,000 IPO Shares to be allocated in the following manner:- 25,948,000 IPO Shares to the Malaysian public; and- 16,250,000 IPO Shares to the eligible directors and employees of Seng Fong and its subsidiaries (Group) and persons who have contributed to the success of the Group;(B) Institutional offering of 118,676,300 IPO Shares to be allocated in the following manner:- 64,870,000 IPO Shares by way of private placement to Bumiputera investors approved by the Ministry of International Trade and Industry ("MITI"); and- 53,806,300 IPO Shares by way of private placement to other institutional and selected investors.A total of 3,968 applications for 106,046,800 IPO Shares with a value of RM79,535,100 were received from the Malaysian public, which represents an overall oversubscription rate of 3.09 times. For the Bumiputera public portion, a total of 2,097 applications for 31,762,400 IPO Shares were received, which represents an oversubscription rate of 1.45 times. For the remaining Malaysian public portion, a total of 1,871 applications for 74,284,400 IPO Shares were received, which represents an oversubscription rate of 4.73 times.Meanwhile, the 16,250,000 IPO Shares available to the eligible directors and employees of the Group and persons who have contributed to the success of the Group have also been fully subscribed.Managing Director of Seng Fong, Mr. Er Hock Lai said, "We would like to thank investors for their response to our IPO as this is an indication of their confidence in the fundamentals of the business. We can now look forward to capture opportunities arising from the increasing demand from existing customers as well as from new customers as we ramp up production through the hiring of more people for a second shift and implementing ESG initiatives to make our business more sustainable."Group Managing Director/ Chief Executive Officer of Hong Leong Investment Bank, Ms. Lee Jim Leng said: "We are pleased with the reception from investors to Seng Fong's IPO reflecting their confidence in the solid fundamentals of the business and in the leadership as well as vision of the founders and promoters." Hong Leong Investment Bank Berhad is the Principal Adviser, Underwriter and Placement Agent for the IPO.The notices of allotment will be posted to all successful applicants on or before 6 July 2022. The company will list on the Main Market of Bursa Malaysia Securities Berhad on 7 July 2022.Seng Fong Holdings Bhd: http://sengfongholdings.com/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Resource Centre to Offer Pioneering Holistic Renal Care via New Venture ACN Newswire

Malaysian Genomics Resource Centre to Offer Pioneering Holistic Renal Care via New Venture

June 23, 2022
PETALING JAYA, Malaysia, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is acquiring a 51% stake in Aquahealth Sdn Bhd, a kidney dialysis operator, from Rinani Renal Berhad.En. Sasha Nordin, Chief Executive Officer of Malaysian GenomicsAquahealth is establishing a kidney dialysis centre in Gombak, Selangor, with the license to operate the centre owned by the Malaysia International Islamic Chamber of Commerce. With the acquisition of the stake, Malaysian Genomics, through its wholly-owned subsidiary, MGRC Healthcare Sdn Bhd, will now become the operator of the dialysis centre.En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, "This will be the first of many centres across the country that will be driven by a personalised kidney care model integrating dialysis with nutrition management, lifestyle changes, and even genetic testing of patients and their immediate family members. This pioneering approach will focus on bringing innovations in service delivery to improve the lives of patients with chronic kidney disease.""Expanding downstream to healthcare services, through our subsidiary MGRC Healthcare, is an important step in Malaysian Genomics' growth as a diversified specialist healthcare group. The acquisition of the Aquahealth stake is part of our Group's strategy to secure a diverse portfolio of earnings accretive assets across Southeast Asia that will, in turn, leverage and benefit from our genomics and biopharmaceutical knowledge and experience developed over the past 18 years."According to the Ministry of Health's Management of Chronic Kidney Disease report, the number of Malaysians with kidney disease is projected to increase significantly in the future mainly due to the prevalence of diabetes, hypertension and an aging population[1]. At 13.2% per year, Malaysia has the second highest annual growth rate of chronic kidney disease in the world[2].Dato' Dr. Suhaini Kadiman, Chairman of Malaysia International Islamic Chamber of Commerce and Director of Clinical Research at Institute Jantung Negara added, "Thousands of kidney patients are on waiting lists for dialysis treatment and new centres are urgently needed. We welcome MGRC Healthcare's interest to collaborate with us to operate the centre in Gombak, and we look forward to the innovations they will contribute to improve the lives of kidney dialysis patients."Recently, Minister of Health YB Tuan Khairy Jamaluddin noted that there were over 40,000 kidney patients in Malaysia, with over 8,000 new patients diagnosed annually since 2018[3].[1] https://tinyurl.com/42jexjsk[2] https://tinyurl.com/2cmkmzkz[3] https://tinyurl.com/mr3mkfmkMalaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More